Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (735)	5/14/1999 3:00:00 PM
From: ogod	Respond to of 2344

the point is that axo managed to cull a whole lot more money, for what is a close cousin to bra s product line in spite of a pending lawsuit, where it not for the fact that yorkton crammed ca 40m down bra s throat last year they would be out of cash today,

To: StockMiser who wrote (735)	5/14/1999 4:10:00 PM
From: StockMiser	Read Replies (1) \| Respond to of 2344

Biomira rumor is "official".... streetq.com Insider Whispers: Biomira's New Drug According to sources, Biomira (BIOM), and their phase 3 breast cancer vaccine Theratope, will be featured in a NY Times article on Monday focusing on the new therapuetic "cancer vaccines". Imclone and others will also be featured. Interviews can be confirmed with participating companies. The article will coincide with the Atlanta ASCO (American Society of Clinical Oncology) conference starting Saturday. On a similar note, StreetQ has learned that Biomira is in talks with Chiron and at least one other large biotech about a development collaberation with their newest vaccine, BL-25, which is about to begin Phase II clinicals. Pre-clinical data destroyed all lung cancer tumors in mice, and prevented all tumor growth. It is now considered the most powerful cancer therapeutic ever developed. Biomira dropped -5/32 (-2.84%) to close at $5 11/32.